منابع مشابه
Therapeutic drug monitoring of imatinib
In this issue of the Revista Brasileira de Hematologia e Hemoterapia, Martins et al. (1) are publishing an interesting review, a meta-analysis, of the clinical and analytical aspects of therapeutic drug monitoring of imatinib in chronic myeloid leukemia (CML). Imatinib, the archetype for tyrosine kinase inhibitor therapeutics, is an excellent example of intelligent drug development accompanied ...
متن کاملTherapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients
Imatinib mesylate (Glivec®; Novartis, Basel, Switzerland), a protein kinase inhibitor of the BCR–ABL fusion protein, has demonstrated significant clinical efficacy in the treatment of Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML). Imatinib mesylate (hereinafter shortly referred to as imatinib) produces durable responses and prolonged survival; therefore, it has become the...
متن کاملTherapeutic drug monitoring of imatinib--new data strengthen the case.
A population pharmacokinetic study of imatinib in patients with gastrointestinal stromal tumor by Eechoute and colleagues has shown a significant increase in drug clearance over the first 3 months of treatment, resulting in a 30% decrease in drug exposure. This finding clearly shows the possibility of pharmacokinetic resistance in this disease.
متن کاملTherapeutic drug monitoring in CML patients on imatinib.
each, although toxicities were not directly attributed to the agent.2 In their letter, Chamberlain and Glantz comment on the neurologic syndromes we reported and question attribution to liposomal cytarabine. Our attributions were based on 15-year experience in nearly 500 adults with acute lymphoblastic leukemia without central nervous system (CNS) disease, treated with hyperCVAD (cyclophosphami...
متن کاملA Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs
Immunosuppressants require therapeutic drug monitoring because of their narrow therapeutic index and significant inter-individual variability in blood concentrations. This variability can be because of factors like drug-nutrient interactions, drug-disease interactions, renal-insufficiency, inflammation and infection, gender, age, polymorphism and liver mass. Drug monitoring is widely practiced ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2015
ISSN: 0923-7534
DOI: 10.1093/annonc/mdv432.01